Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | John HemptonBronte Capital Amalthea Fund | PharmaceuticalsPharmaceuticals | Short NOVO-B.CO (Novo Nordisk A/S) The manager argues that Novo Nordisk is being outcompeted by Eli Lilly, which has a more effective and better-marketed drug. Consequently, Novo's sales... | BEAR | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Pontus DackmoProtean Select | PharmaceuticalsPharmaceuticals | Long NOVO-B.CO (Novo Nordisk A/S) The fund avoided a major drawdown by choosing to sit out Novo Nordisk's highly-anticipated Cagrisema Phase III study readout, recognizing the risk of crowded positioning. Despite the trial's... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.